Neurocrine Biosciences (NBIX) investor relations material

Executive summary

• Q2 2026 revenue reached $959 million, up 39% year-over-year, driven by strong growth in INGREZZA, CRENESSITY, and the addition of VYKAT XR post-Soleno acquisition.

• Net product sales for the first half of 2026 rose 41.7% year-over-year to $1.77 billion, reflecting successful launches and acquisitions.

• Completed the $2.9 billion acquisition of Soleno Therapeutics in May 2026, integrating VYKAT XR into the rare disease and endocrinology portfolio.

• Multiple clinical milestones are on track for 2027, including phase III data for osavampator (MDD) and direclidine (schizophrenia).

• Expanded commercial teams and promoted a new Chief Business Officer to support growth.

Financial highlights

• INGREZZA net product sales reached $716 million in Q2 2026, up 15% year-over-year; CRENESSITY net sales were $184 million, up 247% year-over-year.

• VYKAT XR contributed $54 million in Q2 post-acquisition; pro-forma Q2 sales were $94 million.

• Q2 2026 GAAP net income was $144.4 million ($1.39 diluted EPS); non-GAAP net income was $297 million ($2.85 EPS).

• Cash, cash equivalents, and marketable securities totaled $482 million at June 30, 2026.

• Operating income for Q2 2026 was $151.5 million, up from $145.6 million in Q2 2025.

Outlook and guidance

• Full-year 2026 INGREZZA net sales guidance raised to $2.825–$2.875 billion, representing ~13% year-over-year growth at the midpoint.

• Management expects continued growth from recent product launches and Soleno integration.

• R&D and SG&A expense guidance increased to support pipeline and commercial expansion.

• Amortization of acquired VYKAT XR IP set at $85–$90 million for 2026.

• Existing capital resources and anticipated sales expected to fund operations for at least the next 12 months.